SEC Form 4 · accession 0001209191-15-051540
SYNAGEVA BIOPHARMA CORP · GEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glen Williams
Officer — SVP, Technical Operations
Period of report
Jun 5, 2015
Accepted (ET)
Jun 9, 2015 · 6:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000911326
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 5, 2015 | A | 25,500 | $0.00 | A | 25,968 | D | |
| Common Stock | Jun 8, 2015 | M | 833 | $40.32 | A | 26,801 | D | |
| Common Stock | Jun 8, 2015 | M | 833 | $57.56 | A | 27,634 | D | |
| Common Stock | Jun 8, 2015 | M | 11,250 | $80.35 | A | 38,884 | D | |
| Common StockF6 | Jun 8, 2015 | S | 10,396 | $214.72 | D | 28,488 | D | |
| Common StockF7 | Jun 8, 2015 | S | 2,520 | $215.72 | D | 25,968 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $40.32 | Jun 8, 2015 | M | 833 | D | — | Jun 6, 2023 | Common Stock | 833 | 20,002 | D |
| Stock Option (Right to Buy)F4 | $57.56 | Jun 8, 2015 | M | 833 | D | — | Oct 4, 2022 | Common Stock | 833 | 13,334 | D |
| Stock Option (Right to Buy)F5 | $80.35 | Jun 8, 2015 | M | 11,250 | D | — | Jun 4, 2024 | Common Stock | 11,250 | 33,750 | D |
Explanation of responses
- F1Award of Restricted Stock Units under the 2014 Equity Incentive Plan. Vests (x) 25% on June 5, 2016 and (y) 12.5% per six months thereafter.
- F2The stock option exercise and sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2015.
- F325% of the total number of shares subject to the option vest and become exercisable on 06/06/2014 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
- F425% of the total number of shares subject to the option vest and become exercisable on 09/24/2013 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
- F525% of the total number of shares subject to the option vest and become exercisable on 06/04/2015 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter
- F6This transaction was executed in multiple trades through a broker-dealer at prices ranging from $214.35 to $215.33. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- F7This transaction was executed in multiple trades through a broker-dealer at prices ranging from $215.38 to $216.17. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.